Since 2015, Novus Acquisition & Development Corporation (NDEV), doing business as Novus Cannabis MedPlan®, has been a pioneering health insurance carrier that integrates THC and CBD cannabis into health plans for both medical and recreational cannabis consumers. With a national network of agents, brokers, and dispensaries, NDEV generates revenue through insurance premiums and provides policyholders access to cannabis and traditional medications through its prescription and cannabis distribution online platform. NDEV’s sustainability is based on its receivable-based business model and has attracted interest from major carriers and InsurTech platforms for plan integration.
Potential investors should consult with their investment professional regarding Novus trading below its intrinsic value. This situation can be evaluated using the Benefit Monetization Ratio, which supports Novus’s long-term vision, sustainable business model, and potential for future growth.
5/12/2025 | ||
3/24/2025 | ||
3/10/2025 | Novus 10k 2024 Press Release | |
2/4/2025 | Novus Cannabis Medplan Unveils Game-Changing Platform | |
11/11/2024 |
Authorized Shares: | 200 million | |
Outstanding Shares: | 126,803,624 | |
Float: | 30,948,730 | |
Par Value: | $0.001 | |
Restricted Shares: | 86,989,251 |
Quote: | Click Here |
Filings: | Click Here |
Pitch Deck: | Click Here |
Investment Highlights Video: | Click Here |
Footnotes:
The platform targeted medical users, unregistered consumers from the illicit market, and recreational users.
Novus is not impacted by the SAFE Banking Act or the process of rescheduling cannabis. As a non-plant-touching company, we encounter fewer legal and regulatory challenges. Insurance providers operate on a state-by-state basis, and since federal cannabis laws do not apply directly to us, we can operate across state and national borders with fewer restrictions.
Explore the Growth Potential of Novus: Novus’s management believes the current stock price presents a possible investment opportunity. This perspective is based on our internal Net Asset Value (NAV) calculation per Share. This is how insurance companies are valued.
Net Asset Value per Share Calculation: To determine the NAV per Share, we first calculated the company’s total Net Asset Value. This figure represents the difference between our total assets and liabilities, clearly showing the company’s underlying intrinsic value. Subsequently, we divided this Net Asset Value by the total number of Shares Issued and Outstanding. This calculation yields the Net Asset Value attributable to each share of Novus stock.
Industry Valuation Multiple: To arrive at our view of potential investment value, we applied an industry-standard valuation multiple of approximately 20 to our calculated Net Asset Value per Share. This multiple is derived from the average trading multiples observed for publicly traded companies within our peer group and broader industry. Using an industry-standard multiple allows for a comparative assessment of Novus’s potential value relative to its competitors.
Alignment with Comparable Valuations: Applying this multiple of approximately 20 is appropriate as it aligns with the prevailing valuations observed for comparable companies within our industry. These companies often share similar business models, growth prospects, and risk profiles, making their valuation metrics potentially relevant benchmarks for Novus.
Reflection of Unique Asset Base: This valuation approach may appropriately reflect Novus’s unique and valuable asset base. Our assets, which contribute significantly to our overall Net Asset Value, possess distinct characteristics and potential that are not fully reflected in the current market price.
Further Information: For a more detailed understanding of our Net Asset Value calculation, the specific components of our asset base, the selection criteria for our industry comparables, and the rationale behind the chosen valuation multiple, we encourage interested parties to visit the Investor Relations section of our website, the materials available on this page provide comprehensive information and transparency regarding our valuation methodology and investment rationale.
Important Disclaimer: Investors must understand that the projections and valuation assessments presented here represent Novus’s management team’s current views and analysis. These are based on information available to us at this time and are subject to various assumptions, market conditions, and inherent uncertainties. Therefore, we strongly advise you to carefully review all available information, conduct your own independent due diligence, and consult with a qualified financial professional before making any investment decisions. Investment in securities involves risk, and past performance is not indicative of future results. Your financial advisor can help you assess your risk tolerance and investment objectives and determine if an investment in Novus suits your portfolio.
* Indicates Required Field
We are available Monday - Friday 9:00 am - 5:00 pm (EST) Email: info@getnovusnow.com
Affiliate can only market to states where Novus MedPlan is licensed. Provider and Members can only sign up in states where Novus MedPlan is licensed. Any technical issues please contact info@getnovusnow.com Copyrights © 2025 Novus Acquisition & Dev. All rights reserved